



NEWS RELEASE

Repligen to Present at Stephens Inc. Fall Investment Conference

2014-11-05

WALTHAM, Mass., Nov. 5, 2014 (GLOBE NEWSWIRE) -- Repligen Corporation (Nasdaq:RGEN) today announced that Walter C. Herlihy, Ph.D., President and Chief Executive Officer, will present at the Stephens Fall Investment Conference on Wednesday, November 12 at 10:00 a.m. EST. The conference will be held at the New York Palace Hotel in New York City.

An audio-only webcast of Dr. Herlihy's remarks and discussion with the audience will be accessible at the time of the presentation through the **Investor Events** section of Company's website. A replay of this webcast will also be accessible for a period of time following the event.

About Repligen Corporation

Repligen Corporation (Nasdaq:RGEN) is a life sciences company focused on the development and commercialization of high-value consumable products used in the process of manufacturing biological drugs. Our bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. We are the leading manufacturer of Protein A affinity ligands, a critical component of Protein A media that is used to separate and purify monoclonal antibody therapeutics. Our ATF (Alternating Tangential Flow) System and our growth factor products are used to increase product yield during the fermentation stage of biologic drug manufacturing. In addition, we developed and market an innovative line of "ready-to-use" chromatography columns under our OPUS® brand (Open-Platform User-Specified) that we deliver prepacked with our customers' choice of purification media. Repligen's corporate headquarters are in Waltham, MA (USA) and our manufacturing facilities are located in Waltham, MA and Lund, Sweden.

This press release may contain forward-looking statements within the meaning of the federal securities laws. Investors are cautioned that statements in this press release which are not strictly historical statements including, without limitation, statements identified by words like "believe," "expect," "may," "will," "should," "seek," or "could" and similar expressions, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including risks discussed from time to time in our filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update any forward-looking statements, except as required by law.

CONTACT: Repligen CorporationSondra Newman
Director Investor Relations
(781) 419-1881
snewman@repligen.com

Source: Repligen Corporation